0001493152-22-007157.txt : 20220317
0001493152-22-007157.hdr.sgml : 20220317
20220317161545
ACCESSION NUMBER: 0001493152-22-007157
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220315
FILED AS OF DATE: 20220317
DATE AS OF CHANGE: 20220317
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fremeau Robert Thomas Jr.
CENTRAL INDEX KEY: 0001894066
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35817
FILM NUMBER: 22748712
MAIL ADDRESS:
STREET 1: C/O VYANT BIO, INC.
STREET 2: 2370 STATE ROUTE 70 WEST, SUITE 310
CITY: CHERRY HILL
STATE: NJ
ZIP: 08002
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vyant Bio, Inc.
CENTRAL INDEX KEY: 0001349929
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 043462475
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2370 STATE ROUTE 70 WEST
STREET 2: SUITE 310
CITY: CHERRY HILL,
STATE: NJ
ZIP: 08002
BUSINESS PHONE: 201.528.9200
MAIL ADDRESS:
STREET 1: 2370 STATE ROUTE 70 WEST
STREET 2: SUITE 310
CITY: CHERRY HILL,
STATE: NJ
ZIP: 08002
FORMER COMPANY:
FORMER CONFORMED NAME: CANCER GENETICS, INC
DATE OF NAME CHANGE: 20111216
FORMER COMPANY:
FORMER CONFORMED NAME: CANCER GENETICS INC
DATE OF NAME CHANGE: 20060117
4
1
ownership.xml
X0306
4
2022-03-15
0
0001349929
Vyant Bio, Inc.
VYNT
0001894066
Fremeau Robert Thomas Jr.
C/O VYANT BIO, INC. 2 EXECUTIVE CAMPUS
2370 STATE ROUTE 70, SUITE 310
CHERRY HILL,
NJ
08002
0
1
0
0
Chief Scientific Officer
Stock option (right to buy)
1.00
2022-03-15
4
A
0
75000
0
A
2032-03-15
Common Stock
75000
75000
D
The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application ("IND") with the U.S. Food and Drug Administration ("FDA") for a New Chemical Entity ("NCE") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date.
/s/ Andrew LaFrence, attorney-in-fact
2022-03-17